IL-4 and IL-13 inhibitor Dupixent (dupilumab) has started a priority review at the FDA and is the first biologic drug to show an improvement in remission and symptoms in BP, and the first to allow ...

The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...

There were no AEs leading to death in the Dupixent group and 2 AEs leading to death in the placebo group. In February, the U.S. Food and Drug Administration (FDA) accepted for Priority Review the ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...

the FDA has granted priority review, with a decision expected by June 2025. If approved, Dupixent could tap into yet another lucrative market, further cementing its blockbuster status. With a ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...